Top 5 Most-Read Lung Cancer Articles of 2023

Our most-read content for lung cancer this year included results of a phase 3 trial for treatment of non–small cell lung cancer (NSCLC), clinical guideline updates from the National Comprehensive Cancer Network (NCCN), and a potential link between antidepressants and lung cancer risk.

Here are the top articles on lung cancer for 2023.

5. Study Finds Patient Navigation Program Increases lung Cancer Screening Rates in Urban Setting

An abstract that was presented during the American Society of Clinical Oncology Annual Meeting shows there were disparities in screening rates in urban, multiethnic communities, and patient navigation increased the rates of screening. Of the 360 patients who were included in the study who were seen at 4 sites in a large community health center in Rhode Island, 28% received a low-dose CT scan, which was higher than the overall rate of scans in Rhode Island, which is 13%. Forty-six percent reported that they were not familiar with the screening process for lung cancer and 58% did not recall being told about lung cancer screening by a primary care provider.

Read the full article here.

4. PAPILLON Study Meets Clinical End Point in Patients With EGFR Exon 20 Insertion–Mutated Advanced NSCLC

A phase 3 study met its primary end point, establishing that amivantamab-vmjw (Rybrevant, Janssen)) was able to improve progression-free survival for adults with recently diagnosed locally advanced or metastatic NSCLC. This result was seen when the treatment was used in conjunction with chemotherapy vs chemotherapy alone. The treatment was found to be safe, and although 65% of the population experienced an infusion-related reaction on day 1 of the study, this fell to 3.4% for the day 2 infusion, 0.4% for the week 2 infusion, and 1.1% for the subsequent infusions; 97% of the infusion-related reactions were grade 1.

Read the full article here.

3. NCCN Guideline Update Reflects Rise of Precision Options in NSCLC

An article published in Evidence-Based Oncology^™, sister publication to The American Journal of Managed Care^®, analyzed the new clinical guidelines that were published by the NCCN in December 2022. These new guidelines for treating NSCLC included new therapeutic options like adjuvant therapy, adagrasib, amivantamab, and lorlatinib. Updated language for the pretreatment evaluation and genomic and blood testing were also included to further clarify treatment of NSCLC.

Read the full article here.

2. Tumor-Associated Autoantibodies Demonstrate Promise as Immunotherapy Biomarkers in NSCLC

Two panels that were developed to measure levels of tumor-associated antibodies (TAAbs) could help to predict therapeutic response and the adverse events (AEs)after immune checkpoint inhibitor (ICI)–based treatment in patients with advanced NSCLC. A 7-TAAb panel was used for the study and was found to be a predictor of progression-free survival when using a Cox regression analysis, as patients had an increased risk of disease progression after having ICI-based treatment when they had positive panel results compared with patients with negative results. Meanwhile, a 4-TAAb panel was developed to predict the risk of immune-related adverse events.

Read the full article here.

1. Meta-Analysis Shows Certain Antidepressants May Increase Lung Cancer Risk

Serotonin and norepinephrine reuptake inhibitors could increase the risk of lung cancer, although the effect on survival was not significant. A meta-analysis that looked at 11 studies found that these antidepressants were associated with an 11% higher risk of lung cancer, with a 1.11 pooled risk ratio (95% CI, 1.02-1.20). Patients who had lung cancer and needed antidepressants did not have a statistically different survival outcome compared with patients with lung cancer who did not need antidepressants.

Read the full article here.